{
    "clinical_study": {
        "@rank": "83981", 
        "arm_group": {
            "arm_group_label": "GSK2402968", 
            "arm_group_type": "Experimental", 
            "description": "Comparison of different dose levels"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether an escalating dose of GSK2402968 is\n      effective in the treatment of boys with Duchenne muscular dystrophy resulting from a\n      mutation thought to be corrected by exon 51 skipping."
        }, 
        "brief_title": "Open Label Escalating Dose Pilot Study of PRO051 (GSK2402968) in Duchenne Muscular Dystrophy", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Muscular Dystrophies", 
        "condition_browse": {
            "mesh_term": [
                "Muscular Dystrophy, Duchenne", 
                "Muscular Dystrophies"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Boys aged between 5 and 16 years inclusive.\n\n          -  Duchenne muscular dystrophy resulting from a mutation correctable by treatment with\n             PRO051.\n\n          -  Not ventilator dependent.\n\n          -  Life expectancy of at least six months.\n\n          -  No previous treatment with investigational medicinal treatment within six months\n             prior to the study.\n\n          -  Willing and able to adhere to the study visit schedule and other protocol\n             requirements.\n\n        Exclusion Criteria:\n\n          -  Aberrant RNA splicing and/or aberrant response to PRO051, detected by in vitro PRO051\n             assay during screening.\n\n          -  Known presence of dystrophin in 5% of fibers in a pre-study diagnostic muscle biopsy.\n\n          -  Severe muscle abnormalities defined as increased signal intensity in >50% of the\n             tibialis anterior muscle at MRI.\n\n          -  FEV1 and/or FVC <60% of predicted.\n\n          -  Current or history of liver or renal disease.\n\n          -  Acute illness within 4 weeks prior to treatment (Day 1) which may interfere with the\n             measurements.\n\n          -  Severe mental retardation which in the opinion of the investigator prohibits\n             participation in this study.\n\n          -  Severe cardiac myopathy which in the opinion of the investigator prohibits\n             participation in this study.\n\n          -  Need for mechanical ventilation.\n\n          -  Creatinine concentration above 1.5 times the upper limit of normal (age corrected).\n\n          -  Serum ASAT and/or ALAT concentration(s) which suggest hepatic impairment.\n\n          -  Use of anticoagulants, antithrombotics or antiplatelet agents.\n\n          -  Subject has donated blood less than 90 days before the start of the study.\n\n          -  Current or history of drug and/or alcohol abuse.\n\n          -  Participation in another trial with an investigational product."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "16 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01910649", 
            "org_study_id": "114673", 
            "secondary_id": "2007-004819-54"
        }, 
        "intervention": {
            "arm_group_label": "GSK2402968", 
            "description": "Subcutaneous", 
            "intervention_name": "GSK2402968", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "drisapersen", 
        "lastchanged_date": "April 3, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess the Effect, Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Doses of PRO051 in Patients With Duchenne Muscular Dystrophy", 
        "overall_official": {
            "affiliation": "UZ Leuven", 
            "last_name": "N Goemans, Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Belgium: Local Medical Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Summarized per dose group", 
                "measure": "Acute phase: Safety data", 
                "safety_issue": "No", 
                "time_frame": "18 weeks"
            }, 
            {
                "description": "Plasma concentration versus time profiles of PRO051 (GSK2402968)", 
                "measure": "Acute phase and Continued Treatment Phase : Pharmacokinetics measured by T1/2, Cmax, Ctrough, 7d, tmax, and volume of distribution and clearance", 
                "safety_issue": "No", 
                "time_frame": "18 weeks"
            }, 
            {
                "description": "Change from baseline and summarized values", 
                "measure": "Acute phase and Continued Treatment Phase : Safety as assessed by the collection of adverse events (AEs)", 
                "safety_issue": "No", 
                "time_frame": "72 weeks"
            }, 
            {
                "description": "Change from baseline and summarized values", 
                "measure": "Continued Treatment Phase :Safety as assessed by laboratory parameters", 
                "safety_issue": "No", 
                "time_frame": "72 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01910649"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Acute phase: Production of exon skip 51 messenger Ribonucleic acid (mRNA)", 
                "safety_issue": "No", 
                "time_frame": "18 weeks"
            }, 
            {
                "measure": "Acute phase: Presence of dystrophin expression", 
                "safety_issue": "No", 
                "time_frame": "18 weeks"
            }, 
            {
                "description": "Timed tests and 6-minutes walk", 
                "measure": "Acute phase: Muscle function", 
                "safety_issue": "No", 
                "time_frame": "18 weeks"
            }, 
            {
                "description": "Quantitative Muscle Testing [QMT]- Cooperative International Neuromuscular Research Group (CINRG) and Manual Muscle Testing [MMT]", 
                "measure": "Acute phase: Muscle strength", 
                "safety_issue": "No", 
                "time_frame": "18 weeks"
            }, 
            {
                "measure": "Continued Treatment Phase: Exon skip efficiency", 
                "safety_issue": "No", 
                "time_frame": "72 weeks"
            }, 
            {
                "measure": "Continued Treatment Phase Dystrophin expression in muscle biopsy", 
                "safety_issue": "No", 
                "time_frame": "72 weeks"
            }, 
            {
                "description": "Timed tests and 6-minutes walk", 
                "measure": "Continued Treatment Phase: Muscle function", 
                "safety_issue": "No", 
                "time_frame": "72 weeks"
            }, 
            {
                "description": "Handheld myometry and spirometry", 
                "measure": "Continued Treatment Phase: Muscle strength", 
                "safety_issue": "No", 
                "time_frame": "72 weeks"
            }
        ], 
        "source": "Prosensa Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Prosensa Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2008", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}